Search results
Results From The WOW.Com Content Network
Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ:SAVA). As the ...
Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...
As I discussed in my last article on Cassava Sciences (NASDAQ:SAVA), controversy continues to weigh on the performance of SAVA stock. Over the past week, shares in the clinical-stage biotech firm ...
This news caused the stock, at one time a meme favorite, to tank. It fell from well over $100 to less than $50 per share. SAVA stoc ... (NASDAQ:SAVA) has had a big issue that’s weighed on SAVA ...
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
Not long afterward, however, Cassava disputed the legitimacy of that report. These twists and turns in the ongoing story make it difficult to recommend SAVA stock with confidence now. Let’s ...
The stock market is full of ups and downs, which isn’t necessarily a bad thing. Shares of clinical-stage biotechnology company Cassava Sciences (NASDAQ:SAVA) are prone to peaks and valleys, but ...
Cassava Sciences (NASDAQ:SAVA) is a clinical-stage biotechnology company that is taking on Alzheimer’s disease. In the past several months, short-sellers, law firms and other detractors have ...